- Home
- SLN vs LOCO Comparison
SLN vs LOCO Comparison
Compare SLN & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- LOCO
- Stock Information
- Founded
- SLN 1994
- LOCO 1980
- Country
- SLN United Kingdom
- LOCO United States
- Employees
- SLN N/A
- LOCO N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- LOCO Restaurants
- Sector
- SLN Health Care
- LOCO Consumer Discretionary
- Exchange
- SLN Nasdaq
- LOCO Nasdaq
- Market Cap
- SLN 345.3M
- LOCO 323.7M
- IPO Year
- SLN N/A
- LOCO 2014
- Fundamental
- Price
- SLN $6.24
- LOCO $10.64
- Analyst Decision
- SLN Buy
- LOCO Buy
- Analyst Count
- SLN 6
- LOCO 2
- Target Price
- SLN $39.67
- LOCO $18.00
- AVG Volume (30 Days)
- SLN 213.8K
- LOCO 330.2K
- Earning Date
- SLN 11-07-2025
- LOCO 10-30-2025
- Dividend Yield
- SLN N/A
- LOCO N/A
- EPS Growth
- SLN N/A
- LOCO 13.62
- EPS
- SLN N/A
- LOCO 0.89
- Revenue
- SLN $27,169,000.00
- LOCO $480,815,000.00
- Revenue This Year
- SLN N/A
- LOCO $6.13
- Revenue Next Year
- SLN N/A
- LOCO $1.56
- P/E Ratio
- SLN N/A
- LOCO $11.97
- Revenue Growth
- SLN 22.28
- LOCO 2.09
- 52 Week Low
- SLN $1.97
- LOCO $8.29
- 52 Week High
- SLN $18.24
- LOCO $13.24
- Technical
- Relative Strength Index (RSI)
- SLN 46.82
- LOCO 65.44
- Support Level
- SLN $7.06
- LOCO $8.99
- Resistance Level
- SLN $7.39
- LOCO $10.83
- Average True Range (ATR)
- SLN 0.58
- LOCO 0.39
- MACD
- SLN -0.12
- LOCO 0.16
- Stochastic Oscillator
- SLN 21.87
- LOCO 89.70
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.